Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Total Revenues	$ 367	$ 437
Costs and Expenses:
Production costs	884	1,183
Research and development	4,778	4,098
General and administrative	6,201	6,572
Total Costs and Expenses	11,863	11,853
Operating loss	(11,496)	(11,416)
Interest and other income (expense)	46	88
Interest expense and finance costs	(502)	(139)
Settlement of litigation	474
Fair value of convertible note adjustment	(582)
Redeemable warrants valuation adjustment	1,165	2,417
Gain from sale of income tax operating losses	859	791
Gain on sale of building	223
Net loss	(9,813)	(8,259)
Other Comprehensive Income (Loss)
Unrealized gain (loss) on securities	(23)	33
Reclassification adjustments for realized gain (loss) on sales of short-term marketable securities and for impairment losses on investments included in net loss	9	(17)
Net comprehensive loss	$ (9,827)	$ (8,243)
Basic and diluted loss per share	$ (0.22)	$ (0.29)
Weighted average shares outstanding basic and diluted	44,189,217	28,676,076
US [Member]
Revenues:
Clinical treatment programs	$ 248	$ 102
Europe [Member]
Revenues:
Clinical treatment programs	$ 119	$ 335